Insight

partnering360® also provides insightful content that gives executives a partnering edge. Tune in here to see high-profile panels, workshops, and interviews with leading dealmakers.

BIO-Europe Spring 2012

Early stage financing: European and US VCs weigh in

Mar 19, 2012

Is there a recipe for current VCs for successful investing in early stage science? Will recent initiatives from both government and industry help or hurt the venture industry?

view full session here

Are orphan indications the only viable model for drug development?

Mar 19, 2012

The opening plenary addresses orphan indications as a viable model for drug development. Panelists discuss development strategies and the future of personalized medicine.

view full session here

The opportunity of community drug development partnerships for personalized oncology and drug development

Mar 19, 2012

Will community drug development partnerships among academic institutions, diagnostics companies, technology providers and bio/pharma lead to more effective cancer drugs?

view full session here

Advanced therapies: Stem cell and immunotherapy promises in practice

Mar 19, 2012

This panel examines major clinical and commercial developments in using stem cells as drug discovery platforms, as well as the development of immunotherapies to treat cancer.

view full session here

Unconventional deals to herculean strategies

Mar 19, 2012

New realities in healthcare have caused investors to lean toward non-traditional dealmaking strategies. Panelists explore multifaceted, powerful, even herculean, strategies.

view full session here

Next generation anticancer approaches: Innovation meets commercial realities

Mar 20, 2012

This discussion focuses on how commercial realities meet innovation within oncology, covering challenges companies face as oncology becomes increasingly competitive. 

view full session here

Biotech Showcase 2012

Getting a drug approved as the FDA Is evolving

Jan 11, 2012

Despite the FDA’s new Innovation Initiative, there is still the need for companies with drugs in advanced stages of development to have a strategy to get them approved.

view full session here

Reimbursement: A critical component of valuation

Jan 09, 2012

Panelists discuss high level strategies for obtaining coverage and maximizing payment amounts for products in today’s environment and under evolving CMS standards.

view full session here

Alternative financing options for life science companies

Jan 10, 2012

This workshop focuses on what tools an emerging company can use to finance their development programs, including a discussion on debt, royalty and government backed options.

view executive recap here view full session here

The 2nd annual Regenerative Medicine State of the Industry briefing

Jan 10, 2012

The Alliance for Regenerative Medicine presents a briefing on the state of the cell therapy and regenerative medicine industries, including major clinical developments. 

view full session here

Molecular diagnostics: A sector of increasing importance

Jan 11, 2012

Experienced MDx developers, investors, dealmakers and policy advocates explore the challenges and opportunities within the MDx sector, including partnering your product.

view executive recap here view full session here

Redefining exit options given the current economic climate

Jan 09, 2012

Panelists discuss liquidity options for their portfolio companies, risk reduction deal structures they are proposing, and funding options being adopted by management.

view full session here

Life sciences innovation: The struggle to retain and attract investors

Jan 11, 2012

Many VCs are eliminating investments in US life science companies or shifting focus because of perceived regulatory obstacles. How can companies address these obstacles?

view executive recap here view full session here

Infectious disease: Fighting the #2 global killer

Jan 09, 2012

According to the WHO, almost a quarter of deaths globally are due to infectious diseases, but there are promising new approaches in the war against these killers.

view executive recap here view full session here

BIO-Europe 2011

Fostering early stage partnerships among pharma and academia

Oct 31, 2011

Pharma companies are turning to academic institutions to foster early stage partnerships. How do pharma and academia overcome conflicting core values, rights to IP, and more?

view full session here

Unconventional partnerships executed

Oct 31, 2011

With innovation no longer focusing solely on new drugs but on products that will improve patient outcomes, pharma is turning to new players to implement these changes.

view executive recap here view full session here

The rapid evolution of personalized oncology

Oct 31, 2011

If pharma and biotech are now embracing a personalized approach to oncology drug development, what capabilities are now required for them to succeed? 

view executive recap here view full session here

Nanomedicine: The path to personalized medicine?

Oct 31, 2011

Nanotechnology is best known as a drug delivery method, but increasingly companies are applying the special characteristics of nanomedicine to therapeutic drug development. 

view executive recap here view full session here

Regenerative medicine and cell therapy: The road to commercialization

Oct 31, 2011

Leaders in regenerative medicine discuss the outlook for regenerative medicine breakthroughs and therapies, focusing on key regulatory issues and commercial requirements.

view full session here

BioPharm America 2011

Drug development in an evolving healthcare ecosystem

Sep 07, 2011

As healthcare heads away from the blockbuster model toward individualized medicine, biotech and pharma need to engage in non-traditional partnerships with diverse players.

view full session here

140 characters to success: The new frontier of #partnering strategy @work

Sep 08, 2011

A panel of social-media-savvy dealmakers engages in a lively roundtable discussion about using social media to help achieve your business objectives. 

view full session here

Industry outlook: Potential breakthroughs in regenerative medicine in the next three to five years

Sep 09, 2011

The pace of regenerative medical research has accelerated over the past 20 years. What significant breakthroughs are coming in the next three to five years?

view full session here